SEARCH

SEARCH BY CITATION

References

  • 1
    Koide T. Human histidine-rich glycoprotein gene: evidence for evolutionary relatedness to cystatin supergene family. Thromb Hes 1988; 8: 917.DOI: 10.1016/0049-3848(88)90158-2
  • 2
    Falquerho L, Patey G, Paquereau L, Rossi V, Lahuna O, Szpirer J, Szpirer C, Levan G, Le Cam A. Primary structure of the rat gene encoding an inhibitor of the insulin receptor tyrosine kinase. Gene 1991; 98: 20916.DOI: 10.1016/0378-1119(91)90175-B
  • 3
    Kitamura N, Kitagawa H, Fukushima D, Takagaki Y, Miyata T, Nakanishi S. Structural organization of the human kininogen gene and a model for its evolution. J Biol Chem 1985; 260: 86107.
  • 4
    Leung LL, Harpel PC, Nachman RL. Platelet histidine-rich glycoprotein. Meth Enzymol 1989; 169: 26876.
  • 5
    Lijnen HR, Van Hoef B, Collen D. Interaction of heparin with histidine-rich glycoprotein and with antithrombin III. Thromb Haemost 1983; 50: 5602.
  • 6
    Kazama Y, Koide T. Modulation of protein C inhibitor activity by histidine-rich glycoprotein and platelet factor 4. Role of zinc and calcium ions in the heparin-neutralizing ability of histidine-rich glycoprotein. Thromb Haemost 1992; 67: 505.
  • 7
    Lijnen HR, Hoylaerts M, Collen D. Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. J Biol Chem 1980; 255: 1021422.
  • 8
    Saez CT, Jansen GJ, Smith A, Morgan WT. Interaction of histidine-proline-rich glycoprotein with plasminogen: effect of ligands, pH, ionic strength, and chemical modification. Biochemistry 1995; 34: 2496503.
  • 9
    Leung LL. Interaction of histidine-rich glycoprotein with fibrinogen and fibrin. J Clin Invest 1986; 77: 130511.
  • 10
    Shigekiyo T, Ohshima T, Oka H, Tomonari A, Azuma H, Saito S. Congenital histidine-rich glycoprotein deficiency. Thromb Haemost 1993; 70: 2635.
  • 11
    Souto JC, Gari M, Falkon L, Fontcuberta J. A new case of hereditary histidine-rich glycoprotein deficiency with familial thrombophilia. Thromb Haemost 1996; 75: 3745.
  • 12
    Shigekiyo T, Yoshida H, Kanagawa Y, Satoh K, Wakabayashi S, Matsumoto T, Koide T. Histidine-rich glycoprotein (HRG) Tokushima 2: novel HRG deficiency, molecular and cellular characterization. Thromb Haemost 2000; 84: 6759.
  • 13
    Borza DB, Tatum FM, Morgan WT. Domain structure and conformation of histidine-proline-rich glycoprotein. Biochemistry 1996; 35: 192534.
  • 14
    Jones AL, Hulett MD, Parish CR. Histidine-rich glycoprotein binds to cell-surface heparan sulfate via its N-terminal domain following Zn2+ chelation. J Biol Chem 2004; 279: 3011422.DOI: 10.1074/jbc.M401996200
  • 15
    Borza DB, Morgan WT. Histidine-proline-rich glycoprotein as a plasma pH sensor. Modulation of its interaction with glycosaminoglycans by pH and metals. J Biol Chem 1998; 273: 54939.
  • 16
    Jones AL, Hulett MD, Altin JG, Hogg P, Parish CR. Plasminogen is tethered with high affinity to the cell surface by the plasma protein, histidine-rich glycoprotein. J Biol Chem 2004; 279: 3826776.DOI: 10.1074/jbc.M406027200
  • 17
    Guthans SL, Morgan WT. The interaction of zinc, nickel and cadmium with serum albumin and histidine-rich glycoprotein assessed by equilibrium dialysis and immunoadsorbent chromatography. Arch Biochembiophys 1982; 218: 3208.DOI: 10.1016/0003-9861(82)90350-2
  • 18
    Morgan WT. The histidine-rich glycoprotein of serum has a domain rich in histidine, proline, and glycine that binds heme and metals. Biochemistry 1985; 24: 1496501.
  • 19
    Saigo K, Shatsky M, Levitt LJ, Leung LK. Interaction of histidine-rich glycoprotein with human T lymphocytes. J Biol Chem 1989; 264: 824953.
  • 20
    Chang NS, Leu RW, Rummage JA, Anderson JK, Mole JE. Regulation of complement functional efficiency by histidine-rich glycoprotein. Blood 1992; 79: 297380.
  • 21
    Gorgani NN, Parish CR, Easterbrook Smith SB, Altin JG. Histidine-rich glycoprotein binds to human IgG and C1q and inhibits the formation of insoluble immune complexes. Biochemistry 1997; 36: 665362.
  • 22
    Juarez JC, Guan X, Shipulina NV, Plunkett ML, Parry GC, Shaw DE, Zhang JC, Rabbani SA, McCrae KR, Mazar AP, Morgan WT, Donate F. Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain. Cancer Res 2002; 62: 534450.
  • 23
    Donate F, Juarez JC, Giuan X, Shiplina NV, Plonhett ML, Tel-Tsur Z, Shaw DE, Morgon WT, Mazar AP. Peptides derived from the histidine-proline domain of the histidine-proline-rich glycoprotein bind to tropomyosin and have antiangiogenic and antitumor activities . Cancer Res 2004; 64: 581217.
  • 24
    Jahnen-Dechent W, Schinke T, Trindl A, Muller-Esterl W, Sablitzky F, Kaiser S, Blessing M. Cloning and targeted deletion of the mouse fetuin gene. J Biol Chem 1997; 272: 31496503.DOI: 10.1074/jbc.272.50.31496
  • 25
    Schinke T, Koide T, Jahnen-Dechent W. Human histidine-rich glycoprotein expressed in SF9 insect cells inhibits apatite formation. FEBS Lett 1997; 412: 55962.DOI: 10.1016/S0014-5793(97)00827-2
  • 26
    Koide T, Odani S, Ono T. Human histidine-rich glycoprotein: simultaneous purification with antithrombin III and characterization of its gross structure. J Biochem (Tokyo) 1985; 98: 1191200.
  • 27
    Gallimore MJ, Tyler HM, Shaw JT. The measurement of fibrinolysis in the rat. Thromb Diath Haemorrh 1971; 26: 295310.
  • 28
    Wakabayashi S, Takahashi K, Koide T. Structural characterization of the gene for human histidine-rich glycoprotein, reinvestigation of the 5′-terminal region of cDNA and a search for the liver specific promoter in the gene. J Biochem (Tokyo) 1999; 125: 52230.
  • 29
    Denecke B, Gräber S, Schäfer C, Heiss A, Wöltje M, Jahnen-Dechent W. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J 2003; 376: 13545.DOI: 10.1042/BJ20030676
  • 30
    Gorgani NN, Smith BA, Kono DH, Theofilopoulos AN. Histidine-rich glycoprotein binds to DNA and Fc gamma RI and potentiates the ingestion of apoptotic cells by macrophages. J Immunol 2002; 169: 474551.
  • 31
    Davie EW, Hanahan DJ. Blood coagulation proteins. In: Putnam, FW, ed. The Plasma Proteins, Vol. 3. New York: Academic Press, 1977, 421544.
  • 32
    Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med 1975; 292: 14651.
  • 33
    Lijnen HR, Hoylaerts M, Collen D. Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. J Biol Chem 1983; 258: 38038.
  • 34
    Lijnen HR, Van Hoef B, Collen D. Histidine-rich glycoprotein modulates the anticoagulant activity of heparin in human plasma. Thromb Haemost 1984; 51: 2668.
  • 35
    Chu AJ, Mathews ST. Poly-l-histidine downregulates fibrinolysis. Blood Coagul Fibrinolysis 2003; 14: 62732.
  • 36
    Leung LL, Harpel PC, Nachman RL, Rabellino EM. Histidine-rich glycoprotein is present in human platelets and is released following thrombin stimulation. Blood 1983; 62: 101621.
  • 37
    Horne MK, 3rd Merryman PK, Cullinane AM. Histidine-proline-rich glycoprotein binding to platelets mediated by transition metals. Thromb Haemost 2001; 85: 8905.
  • 38
    Leung LL, Nachman RL, Harpel PC. Complex formation of platelet thrombospondin with histidine-rich glycoprotein. J Clin Invest 1984; 73: 512.